Indonesia's battle against tuberculosis (TB) is a complex and multifaceted challenge, and the country's efforts to combat this ancient disease are both impressive and crucial. As the second-most affected nation globally, with an estimated 1.09 million cases and 125,000 deaths annually, the stakes are high. The Indonesian government's strategy is a comprehensive approach, combining national plans, regulatory reforms, and innovative solutions, all aimed at achieving the ambitious goal of TB elimination by 2030.
One of the key components of this strategy is the National TB Strategic Plan 2025-2029, which is a strategic roadmap developed through a rigorous national program review. This plan is designed to identify systemic gaps and prioritize actions to strengthen the national TB response. By focusing on case detection, treatment outcomes, and community engagement, the plan aims to address the underlying issues that contribute to the high burden of TB in Indonesia.
The plan's emphasis on community engagement is particularly noteworthy. Indonesia is scaling up village health systems and raising public awareness to address upstream determinants of TB risk, such as smoking, undernutrition, diabetes, and alcohol use disorder. These community-based measures are crucial in preventing new infections and ensuring treatment adherence, as they target the root causes of TB transmission and provide support for those at risk.
Another significant aspect of Indonesia's TB strategy is its investment in vaccine innovation. The country is preparing for the potential introduction of a TB vaccine by 2028 or 2029, with the TB vaccine candidate M72/AS01E entering phase 3 clinical trials in Indonesia. This vaccine has the potential to prevent tuberculosis in adults and could replace the existing BCG vaccine while serving as a booster to enhance its protective effect. Additionally, it is expected to function as a form of immunotherapy or adjuvant treatment, helping to shorten the duration of TB treatment.
The development of this vaccine is a critical step towards large-scale approval and use, with over 2,000 participants involved in the trials nationwide. The success of these trials could pave the way for a broader implementation of the vaccine, which is essential in the fight against TB. However, it is important to note that the challenges of TB elimination are not solely dependent on medical advancements. Underreporting and underdiagnosis remain significant issues, with at least one in four TB cases previously going undetected.
To address these challenges, Indonesia is strengthening its surveillance and data systems, integrating the national TB Information System (SITB) into the Satu Sehat digital health platform. This integration will ensure more accurate and timely reporting across public and private healthcare facilities, helping to identify undiagnosed patients and allocate resources more effectively, particularly among vulnerable groups such as children and people living with HIV.
In conclusion, Indonesia's battle against TB is a testament to the country's commitment to public health and its willingness to tackle a complex and ancient disease. The comprehensive strategy, which includes national plans, regulatory reforms, and vaccine innovation, is a promising step towards achieving the goal of TB elimination. However, the challenges remain significant, and continued efforts are necessary to ensure that no patient is left untreated and to curb ongoing transmission in communities. The success of Indonesia's TB strategy will depend on sustained commitment, effective implementation, and a holistic approach that addresses the social, economic, and medical aspects of this global health challenge.
